Hi Bumskins
I think you will find the best way to analyse this business is by looking at EBITDA rather than accounting profit.
ie the business effectively outlays X amount of capital at Year0 and then receives cash back at Year1 + year2 + year3 + year4 etc. The best proxy for the cash is effectively EBITDA as depreciation is a non cash charge and will also be used as a tax shield to minimise the company's taxable profit.
I am currently in the middle of trying to determine if the business is worth analysing due to my fear that there is very little pricing power and over the long term that means that its difficult to achieve returns above the cost of capital. Would be great if someone could rebut this point.
Cheers.
- Forums
- ASX - By Stock
- can anyone tell me what happen with NXT, I couldn't find any news :-(
NXT
nextdc limited
Add to My Watchlist
1.05%
!
$14.19

Hi Bumskins I think you will find the best way to analyse this...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.19 |
Change
-0.150(1.05%) |
Mkt cap ! $9.087B |
Open | High | Low | Value | Volume |
$14.51 | $14.63 | $14.17 | $35.40M | 2.482M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 32553 | $14.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.28 | 100 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14695 | 14.190 |
4 | 10094 | 14.180 |
1 | 2695 | 14.170 |
4 | 9059 | 14.160 |
1 | 2969 | 14.150 |
Price($) | Vol. | No. |
---|---|---|
14.280 | 100 | 1 |
14.290 | 5808 | 1 |
14.310 | 7418 | 5 |
14.330 | 5808 | 1 |
14.350 | 5808 | 1 |
Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
Featured News
NXT (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online